Shionogi Share Price Jumps After Report Of Crestor Cutting Heart Attack Risk
This article was originally published in PharmAsia News
American Heart Association released a report Nov. 9 that reported cholesterol lowering drug Crestor (rosuvastatin) cut heart attack risk in people with low to normal cholesterol levels. In Tokyo, Shionogi's shares jumped over 11 percent upon hearing the news. (Click here for more - Japanese language
You may also be interested in...
Abbott reported strong sales for diagnostics and devices in the third quarter and raised its full-year EPS guidance to $3.55 per share.
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.
A randomized trial demonstrated the superiority of Medtronic’s DTM spinal cord stimulation waveform over conventional spinal cord stimulation for treating back pain.